RNA vs. PTCT, GLPG, GERN, AMPH, CPRX, SNDX, SDGR, MRVI, GPCR, and NAMS
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include PTC Therapeutics (PTCT), Galapagos (GLPG), Geron (GERN), Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Maravai LifeSciences (MRVI), Structure Therapeutics (GPCR), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences (NASDAQ:RNA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
PTC Therapeutics has a net margin of -66.82% compared to Avidity Biosciences' net margin of -2,219.87%. PTC Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.
PTC Therapeutics received 405 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 64.11% of users gave Avidity Biosciences an outperform vote while only 62.10% of users gave PTC Therapeutics an outperform vote.
Avidity Biosciences presently has a consensus price target of $36.33, suggesting a potential upside of 44.52%. PTC Therapeutics has a consensus price target of $33.53, suggesting a potential upside of 31.97%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Avidity Biosciences is more favorable than PTC Therapeutics.
Avidity Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
Avidity Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, PTC Therapeutics had 7 more articles in the media than Avidity Biosciences. MarketBeat recorded 14 mentions for PTC Therapeutics and 7 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.96 beat PTC Therapeutics' score of 0.87 indicating that Avidity Biosciences is being referred to more favorably in the media.
Summary
Avidity Biosciences beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
